Competitive Assay Patents (Class 435/7.93)
-
Patent number: 8969024Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.Type: GrantFiled: August 27, 2008Date of Patent: March 3, 2015Assignee: AbbVie Biotechnology LtdInventors: Zehra Kaymakcalan, Limin Xiong
-
Patent number: 8962264Abstract: The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment. The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.Type: GrantFiled: March 19, 2007Date of Patent: February 24, 2015Assignees: National University Corporation University of Fukui, JNC CorporationInventor: Sakon Noriki
-
Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
Patent number: 8961977Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.Type: GrantFiled: February 14, 2011Date of Patent: February 24, 2015Assignee: University of RochesterInventors: Stephen Dewhurst, Mark A. Sullivan -
Publication number: 20150050266Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: December 23, 2013Publication date: February 19, 2015Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 8956877Abstract: A separation-free assay including a binding partner, a binding partner labeled with a directly luminescent label, and a nonspecifically binding label able to affect the signal of the unbound labeled binding partner, in which a signal of the binding partner label or the signal of the nonspecific binding label is measured in a binding event, and where at least one of the binding partners is a mobile binding partner.Type: GrantFiled: August 6, 2008Date of Patent: February 17, 2015Assignee: Aqsens OyInventor: Harri Härmä
-
Patent number: 8956823Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.Type: GrantFiled: August 1, 2008Date of Patent: February 17, 2015Assignee: Bio-Rad Laboratories, Inc.Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
-
Publication number: 20150037823Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.Type: ApplicationFiled: June 27, 2014Publication date: February 5, 2015Inventors: Yves Henrotin, Myriam Gharbi, Michelle Deberg, Edwin De Pauw
-
Publication number: 20150037251Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.Type: ApplicationFiled: February 18, 2013Publication date: February 5, 2015Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
-
Publication number: 20150037813Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).Type: ApplicationFiled: July 4, 2012Publication date: February 5, 2015Applicant: FUJIREBIO INC.Inventor: Yoshie GOISHI
-
Publication number: 20150037343Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.Type: ApplicationFiled: July 30, 2014Publication date: February 5, 2015Inventors: Seok Kyun KIM, Sang Yeul Han, Kwang Hoon Lee, Kyung Eun Kim, Chung Ho Kim, Yong In Kim, Hyung-Chan Kim, Yoon Sook Lee, Hyo Seon Lee
-
Publication number: 20150031047Abstract: In one non-limiting aspect, the invention provides a method for detecting the quality of a biological molecule comprising forming a first mixture of ingredients comprising: (i) a first binding agent that specifically binds to a tag, wherein the first binding agent is attached to a solid support; (ii) a decoy comprising a first portion comprising the tag attached to a second portion comprising an anchor; (iii) a sensor attached to a second binding agent that specifically binds to the anchor; and (iv) a sample suspected of containing a high quality biological molecule comprising a tag, wherein the tag of the high quality biological molecule is accessible; allowing interaction of the ingredients such that the sensor provides an output signalType: ApplicationFiled: June 20, 2012Publication date: January 29, 2015Applicant: BioScale, Inc.Inventors: Edward Marshall Alderman, Brett Peter Masters, Michael Francis Miller, William Matthew Dickerson
-
Publication number: 20150030603Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.Type: ApplicationFiled: July 29, 2014Publication date: January 29, 2015Inventors: Kyung Eun KIM, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
-
Patent number: 8927225Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.Type: GrantFiled: September 8, 2009Date of Patent: January 6, 2015Assignee: The University of Hong KongInventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
-
Publication number: 20150005192Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Applicant: Cambridge Enterprise LimitedInventors: Sabine Bahn, Paul Guest, Laura Harris, Yishai Levin, Divya Krishnamurthy
-
Publication number: 20150004177Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: June 27, 2014Publication date: January 1, 2015Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
-
Publication number: 20150004634Abstract: Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.Type: ApplicationFiled: September 17, 2014Publication date: January 1, 2015Inventor: Shawn F. Bairstow
-
Publication number: 20140363447Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: ApplicationFiled: August 28, 2014Publication date: December 11, 2014Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20140363450Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.Type: ApplicationFiled: August 12, 2013Publication date: December 11, 2014Applicant: MEDIRISTA BIOTECHNOLOGIES ABInventor: Johan FROSTEGÅRD
-
Patent number: 8900882Abstract: In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analog thereof and substance B or an analog thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.Type: GrantFiled: May 14, 2009Date of Patent: December 2, 2014Assignees: Nitto Boseki Co., Ltd., Shinshu UniversityInventors: Kiyotaka Fujita, Ryo Kojima, Yoshiro Sato, Natsuki Sato
-
Publication number: 20140349956Abstract: The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC.Type: ApplicationFiled: January 16, 2013Publication date: November 27, 2014Inventor: Josef Neu
-
Publication number: 20140349862Abstract: Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles.Type: ApplicationFiled: May 30, 2012Publication date: November 27, 2014Inventor: Vuong Ngoc Trieu
-
Patent number: 8895259Abstract: The invention lies in the area of platelet function diagnostics and relates to an in vitro method for the determination of platelet function under flow conditions. The method is particularly suitable for the determination of the effect of clopidogrel after oral intake and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) receptor antagonists with antithrombotic activity.Type: GrantFiled: April 26, 2007Date of Patent: November 25, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventor: Andreas Rechner
-
Patent number: 8889370Abstract: A homogeneous method of determining inhibitors of proteolytically active coagulation factors (anticoagulants) in a sample, in particular direct thrombin and factor Xa inhibitors, and also a test kit to be used in such a method. Use is made of ligands which bind to the proteolytically active coagulation factor but are not cleaved by the latter and compete with the anticoagulant to be determined.Type: GrantFiled: December 21, 2011Date of Patent: November 18, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Andreas Kappel, Andreas Rechner, Sina Stephan, Thomas Wissel
-
Patent number: 8877927Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R1 and R2 is H, and the other is selected from F and Cl, or R1 and R2 are both F; R3 is selected from cyclopentyl and cyclohexyl; R4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.Type: GrantFiled: January 8, 2009Date of Patent: November 4, 2014Assignee: Grunenthal GmbHInventors: Martin Quibell, John Paul Watts
-
Patent number: 8865412Abstract: Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.Type: GrantFiled: May 28, 2008Date of Patent: October 21, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventor: Shawn F. Bairstow
-
Publication number: 20140295469Abstract: A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding.Type: ApplicationFiled: July 6, 2012Publication date: October 2, 2014Inventors: Diana Julia Leeming, Morten Karsdal, Efstathios Vassiliadis
-
Publication number: 20140295468Abstract: The test substance assay method includes (i) obtaining a mixed solution by mixing (a) first dry particles that are modified with first binding substances exhibiting binding properties specific to a test substance, have an average particle size of 100 nm to 200 nm, and have labels, and (b) second dry particles that are modified with second binding substances not exhibiting binding properties specific to the test substance, have an average particle size of 100 nm to 200 nm, and do not have labels with (c) a test sample solution containing the test substance; (ii) applying the mixed solution onto a substrate; (iii) causing the test substance to be trapped in a reaction site on the substrate that has third binding substances having binding properties specific to the test substance or has substances exhibiting binding properties to the first binding substances; and (iv) detecting the test substance.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: FUJIFILM CorporationInventors: Noriyuki KASAGI, Hiroyuki CHIKU, Dai UJIHARA, Toshihide YOSHITANI
-
Publication number: 20140286953Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.Type: ApplicationFiled: December 11, 2013Publication date: September 25, 2014Applicant: Amgen Inc.Inventors: Barbra Sasu, Mitsuru Haniu, Thomas Charles Boone, Xiao-juan Bi, Grace Ki Jeong Lee, Tara Arvedson, Aaron George Winters, Keegan Cooke, Jackie Z. Sheng
-
Publication number: 20140273034Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Abbott Point of Care Inc.Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
-
Publication number: 20140271945Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Inventors: Xiujuan Hao, Isaac A. Angres
-
Publication number: 20140274766Abstract: Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions.Type: ApplicationFiled: January 15, 2014Publication date: September 18, 2014Inventors: Steven B. Abramson, Mukundan Attur, Glyn Palmer, Ashok Amin
-
Patent number: 8835125Abstract: Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches.Type: GrantFiled: December 16, 2011Date of Patent: September 16, 2014Assignee: Affymetrix, Inc.Inventors: Robert G. Kuimelis, Glenn H. McGall, Stephen P. A. Fodor
-
Publication number: 20140248643Abstract: A chromatographic process for the enrichment of at least one compound of interest from a mixture is proposed, using chromatographic columns, wherein said process involves a sequence of the following steps: (i) a cyclic accumulation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein subsequently columns exchange places and wherein the phases are carried out sequentially; (ii) a cyclic separation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein after these phases columns exchange places to undergo the next interconnected and disconnected phases; and (iii) an elution phase, in which from the column, which at the end of phase (i) or at the end of phase (ii) contains the compound of interest, is extracted via the outlet.Type: ApplicationFiled: January 29, 2014Publication date: September 4, 2014Applicant: CHROMACON AGInventors: Thomas MÜLLER-SPÄTH, Guido STRÖHLEIN, Lars AUMANN, Michael BAVAND, Nicole ULMER
-
Patent number: 8815518Abstract: Disclosed are a detection/quantification kit and a detection/quantification method for detecting/quantifying an analyte rapidly at a low cost and in a simple manner. Specifically, disclosed is a kit for detecting an analyte in a sample, comprising a first conjugate and a second conjugate, wherein the first conjugate comprises a first substance comprising a stimuli-responsive polymer and a first affinity substance having affinity for the analyte and bound to the first substance, and the second conjugate comprises a second substance carrying an electrical charge and a second affinity substance having affinity for the analyte and bound to the second substance. The first and second affinity substances can bind to different sites on the analyte simultaneously.Type: GrantFiled: June 28, 2007Date of Patent: August 26, 2014Assignee: JNC CorporationInventors: Hirokazu Nagaoka, Noriyuki Ohnishi, Kageaki Matsui, Satoru Sugita
-
Publication number: 20140234365Abstract: The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Applicant: ALERE SAN DIEGO, INC.Inventor: Mariusz Banaszczyk
-
Patent number: 8808999Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: GrantFiled: January 18, 2012Date of Patent: August 19, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Patent number: 8809004Abstract: Method, device and kit for the detection of antibodies directed to Feline Immunodeficiency Virus (FIV). The method includes contacting the felid biological sample with FIV env polypeptide and detecting whether the polypeptide substantially binds to the antibody in the biological sample. The method will detect FIV antibodies in a sample from animals that have been naturally infected but the method will not detect antibodies in a sample from animals that have not been infected and that have not been vaccinated with an FIV vaccine after within about the previous five to eight weeks.Type: GrantFiled: April 1, 2011Date of Patent: August 19, 2014Assignee: IDEXX Laboratories, Inc.Inventors: Thomas Patrick O'Connor, Philip Andersen, Randall Groat, Eugene Regis Krah, Jill Saucier
-
Publication number: 20140227725Abstract: The present invention concerns a method for determining the concentration of calprotectin in a sample. A lateral flow test kit and test element using said method are also provided.Type: ApplicationFiled: June 21, 2012Publication date: August 14, 2014Applicant: CALPRO ASInventor: Magne Fagerhol
-
Publication number: 20140219913Abstract: Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Philip Bardwell
-
Publication number: 20140205597Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: December 23, 2013Publication date: July 24, 2014Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 8778699Abstract: A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.Type: GrantFiled: August 4, 2011Date of Patent: July 15, 2014Assignee: Idexx Laboratories, Inc.Inventors: Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
-
Patent number: 8771714Abstract: Provided are systems and methods for detecting and/or measuring in vivo interstitial biological activity, processes, and or compounds in human or animal subjects.Type: GrantFiled: October 31, 2007Date of Patent: July 8, 2014Assignee: MUSC Foundation for Research DevelopmentInventors: Francis G. Spinale, Robert Stroud, Michael Looper, Anne Deschamps
-
Patent number: 8771972Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.Type: GrantFiled: July 19, 2011Date of Patent: July 8, 2014Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20140187438Abstract: Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient Ep-ICD polypeptides and Ep-ICD polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear Ep-ICD polypeptides and optionally EpEx polypeptides are provided. The invention also provides kits and compositions for carrying out the methods of the invention.Type: ApplicationFiled: December 6, 2013Publication date: July 3, 2014Inventors: Paul Walfish, Ranju Ralhan
-
Publication number: 20140178884Abstract: Disclosed herein are methods of diagnosing, monitoring and treating an Aspergillus species-associated condition, such as Aspergillus fumigatus (Af)-associated condition, including aspergillosis, such as invasive aspergillosis (IA). Methods for diagnosing and/or monitoring an Aspergillus species-associated condition, such as IA are provided. Also disclosed are point-of-care immunoassays that can be used to diagnose or monitor the efficacy of an Aspergillus-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by an Aspergillus species, such as Af.Type: ApplicationFiled: May 22, 2012Publication date: June 26, 2014Applicant: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIV. OF NEVADA, RENOInventors: David Aucoin, Thomas R. Kozel, Sindy Chaves
-
Publication number: 20140178908Abstract: A method of competitive immunoassay is provided.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Applicant: SYSMEX CORPORATIONInventors: Keiko YOSHIKAWA, Naoto KOSHIMURA
-
Publication number: 20140178903Abstract: The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.Type: ApplicationFiled: December 28, 2011Publication date: June 26, 2014Applicant: UNIVERSIDAD DE SEVILLAInventors: Carolina Sousa Martin, Isabel Comino Montilla, Ana Real Calderon, Santiago Vivas Alegre, Angel Cebolla Rammirez
-
Publication number: 20140178332Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: January 13, 2014Publication date: June 26, 2014Applicant: ABBVIE INC.Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Patent number: 8759114Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.Type: GrantFiled: June 17, 2013Date of Patent: June 24, 2014Assignee: Stichting Voor de Technische WetenschappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
-
Patent number: 8753823Abstract: The steps of the method are preparing a specific antigen; intravenously injecting prescription medication initially intended for oral consumption into the blood stream of the patient, the prescription medication including an inert binder; creating unnatural antibodies in response to antigenic stimulation; drawing a blood sample from a patient; mixing the drawn blood sample with the prepared specific antigen; and determining the presence of a formation of an antibody-antigen complex indicative of medication initially intended for oral consumption intravenously injected into the blood stream of a patient.Type: GrantFiled: August 24, 2011Date of Patent: June 17, 2014Inventor: Stephen Stefano